Magnetic resonance guided high intensity focused ultrasound (MR-HIFU) effectively reduces fibroid-related symptoms and improves quality of life—A prospective single-centre 12-month follow-up study

IF 3.1 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Acta Obstetricia et Gynecologica Scandinavica Pub Date : 2025-04-29 DOI:10.1111/aogs.15086

Saara Otonkoski, Antti Viitala, Gaber Komar, Teija Sainio, Anna Yanovskiy, Roberto Blanco Sequieros, Antti Perheentupa, Kirsi Joronen

{"title":"Magnetic resonance guided high intensity focused ultrasound (MR-HIFU) effectively reduces fibroid-related symptoms and improves quality of life—A prospective single-centre 12-month follow-up study","authors":"Saara Otonkoski, Antti Viitala, Gaber Komar, Teija Sainio, Anna Yanovskiy, Roberto Blanco Sequieros, Antti Perheentupa, Kirsi Joronen","doi":"10.1111/aogs.15086","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Uterine fibroids are the most common benign tumors among women, and it is estimated that approximately 70% of women have one or multiple fibroids by the age of menopause. About 30% of these women suffer from symptoms related to the fibroids. Magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) is a novel, non-invasive treatment method for symptomatic uterine fibroids.</p>\n </section>\n \n <section>\n \n <h3> Material and Methods</h3>\n \n <p>In this prospective, single-centre follow-up study, 175 women with symptomatic uterine fibroids were treated with MR-HIFU. The effect of MR-HIFU on fibroid symptoms and quality of life was evaluated using a uterine fibroid-specific quality of life questionnaire (UFS-QoL). The main outcome measure was the symptom severity score and quality of life (QoL) before the MR-HIFU and 3 and 12 months after the treatment. This study was registered at clinicaltrials.gov (NCT03937401).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The median symptom severity score decreased from 56 (IQR 44–69) at baseline to 28 (IQR 16–44) at 3 months (<i>p</i> < 0.01) and 25 (IQR 16–38) at 12 months (<i>p</i> < 0.01) after treatment. The QoL score increased from a median of 48 (IQR 33–66) at baseline to 73 (IQR 59–93) at 3 months (<i>p</i> < 0.01) and 78 (IQR 66–90) at 12 months after treatment (<i>p</i> < 0.01). The reintervention rate during the 12-month follow-up was 2%.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>MR-HIFU significantly reduces the severity of fibroid-related symptoms in selected patients as early as 3 months after MR-HIFU. The effect persists at 12 months. There is also a significant improvement in the quality of life 3 months after treatment, which further increases at 12 months.</p>\n </section>\n </div>","PeriodicalId":6990,"journal":{"name":"Acta Obstetricia et Gynecologica Scandinavica","volume":"104 6","pages":"1172-1180"},"PeriodicalIF":3.1000,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/aogs.15086","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Obstetricia et Gynecologica Scandinavica","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/aogs.15086","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Uterine fibroids are the most common benign tumors among women, and it is estimated that approximately 70% of women have one or multiple fibroids by the age of menopause. About 30% of these women suffer from symptoms related to the fibroids. Magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) is a novel, non-invasive treatment method for symptomatic uterine fibroids.

Material and Methods

In this prospective, single-centre follow-up study, 175 women with symptomatic uterine fibroids were treated with MR-HIFU. The effect of MR-HIFU on fibroid symptoms and quality of life was evaluated using a uterine fibroid-specific quality of life questionnaire (UFS-QoL). The main outcome measure was the symptom severity score and quality of life (QoL) before the MR-HIFU and 3 and 12 months after the treatment. This study was registered at clinicaltrials.gov (NCT03937401).

Results

The median symptom severity score decreased from 56 (IQR 44–69) at baseline to 28 (IQR 16–44) at 3 months (p < 0.01) and 25 (IQR 16–38) at 12 months (p < 0.01) after treatment. The QoL score increased from a median of 48 (IQR 33–66) at baseline to 73 (IQR 59–93) at 3 months (p < 0.01) and 78 (IQR 66–90) at 12 months after treatment (p < 0.01). The reintervention rate during the 12-month follow-up was 2%.

Conclusions

MR-HIFU significantly reduces the severity of fibroid-related symptoms in selected patients as early as 3 months after MR-HIFU. The effect persists at 12 months. There is also a significant improvement in the quality of life 3 months after treatment, which further increases at 12 months.

Abstract Image

查看原文本刊更多论文

磁共振引导高强度聚焦超声（MR-HIFU）有效减轻肌瘤相关症状，提高生活质量。一项前瞻性单中心12个月随访研究

子宫肌瘤是女性中最常见的良性肿瘤，据估计，约70%的女性在绝经时患有一个或多个子宫肌瘤。这些妇女中约有30%患有与肌瘤有关的症状。磁共振引导下的高强度聚焦超声（MR-HIFU）是一种新型的、无创的治疗症状性子宫肌瘤的方法。材料和方法：在这项前瞻性、单中心随访研究中，175名有症状的子宫肌瘤妇女接受MR-HIFU治疗。采用子宫肌瘤特异性生活质量问卷（UFS-QoL）评估mri - hifu对肌瘤症状和生活质量的影响。主要结局指标为mri - hifu前、治疗后3个月和12个月的症状严重程度评分和生活质量（QoL）。本研究已在clinicaltrials.gov注册（NCT03937401）。结果：症状严重程度评分中位数从基线时的56分（IQR 44-69）降至3个月时的28分（IQR 16-44） (p)。结论：早在mri - hifu后3个月，所选患者的肌瘤相关症状严重程度就显著降低。这种效果持续12个月。治疗后3个月的生活质量也有显著改善，12个月时进一步提高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Obstetricia et Gynecologica Scandinavica 医学-妇产科学

CiteScore

8.00

自引率

4.70%

发文量

180

审稿时长

3-6 weeks

期刊介绍： Published monthly, Acta Obstetricia et Gynecologica Scandinavica is an international journal dedicated to providing the very latest information on the results of both clinical, basic and translational research work related to all aspects of women’s health from around the globe. The journal regularly publishes commentaries, reviews, and original articles on a wide variety of topics including: gynecology, pregnancy, birth, female urology, gynecologic oncology, fertility and reproductive biology.